GELS Stock Overview

Focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals. More details

GELS fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Earnings have declined by 33.4% per year over past 5 years

Makes less than USD$1m in revenue (A$143K)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Gelteq Limited Competitors

Cadrenal Therapeutics

NasdaqCM:CVKD

US$29.3m

Cognition Therapeutics

NasdaqGM:CGTX

US$31.9m

PolyPid

NasdaqCM:PYPD

US$19.4m

Anebulo Pharmaceuticals

NasdaqCM:ANEB

US$42.0m

Price History & Performance

Summary of share price highs, lows and changes for Gelteq
Historical stock prices
Current Share Price	US$2.48
52 Week High	US$5.50
52 Week Low	US$1.42
Beta	0
1 Month Change	33.33%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-15.65%

Recent updates

Shareholder Returns

	GELS	US Pharmaceuticals	US Market
7D	-4.2%	1.3%	0.6%
1Y	n/a	8.0%	23.8%

Return vs Industry: Insufficient data to determine how GELS performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GELS performed against the US Market.

Price Volatility

Is GELS's price volatile compared to industry and market?
GELS volatility
GELS Average Weekly Movement	51.5%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GELS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GELS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	8	Nathan Givoni	www.gelteq.com

Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.

Gelteq Limited Fundamentals Summary

How do Gelteq's earnings and revenue compare to its market cap?
GELS fundamental statistics
Market cap	US$23.22m
Earnings (TTM)	-US$2.20m
Revenue (TTM)	US$89.08k

262.8x

P/S Ratio

-10.6x

P/E Ratio

Is GELS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GELS income statement (TTM)
Revenue	AU$143.31k
Cost of Revenue	AU$0
Gross Profit	AU$143.31k
Other Expenses	AU$3.69m
Earnings	-AU$3.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.38
Gross Margin	100.00%
Net Profit Margin	-2,474.44%
Debt/Equity Ratio	25.4%

How did GELS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 04:57
End of Day Share Price	2024/12/27 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gelteq Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Gelteq NasdaqCM:GELS Stock Report